Blue Jet Healthcare Ltd
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
- Market Cap ₹ 10,376 Cr.
- Current Price ₹ 598
- High / Low ₹ 1,028 / 492
- Stock P/E 29.4
- Book Value ₹ 72.4
- Dividend Yield 0.20 %
- ROCE 39.8 %
- ROE 30.2 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.8%
Cons
- Stock is trading at 8.26 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 538 | 499 | 683 | 721 | 712 | 1,030 | 1,179 | |
| 325 | 292 | 434 | 502 | 481 | 652 | 739 | |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 440 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 37% |
| 6 | 9 | 19 | 24 | 18 | 46 | 58 | |
| Interest | 7 | 5 | 3 | 1 | 0 | 0 | 5 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 21 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 | 406 | 471 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | |
| 145 | 142 | 182 | 160 | 164 | 305 | 352 | |
| EPS in Rs | 24,118.33 | 1,428.57 | 10.47 | 9.23 | 9.44 | 17.59 | 20.33 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 11% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 63% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 18% |
| TTM: | 102% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 10% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 27% |
| Last Year: | 30% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.60 | 10 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 | 1,221 |
| 74 | 53 | 19 | 5 | 3 | 21 | 21 | |
| 92 | 143 | 173 | 176 | 211 | 263 | 251 | |
| Total Liabilities | 364 | 536 | 713 | 862 | 1,059 | 1,418 | 1,527 |
| 107 | 0 | 156 | 151 | 172 | 300 | 303 | |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 159 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 210 |
| 229 | 497 | 460 | 491 | 489 | 841 | 855 | |
| Total Assets | 364 | 536 | 713 | 862 | 1,059 | 1,418 | 1,527 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 122 | 137 | 146 | 142 | 241 | 46 | |
| -45 | -61 | -76 | -147 | -264 | -35 | |
| -72 | -21 | -56 | -4 | -2 | -19 | |
| Net Cash Flow | 5 | 55 | 14 | -10 | -24 | -8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 |
| Inventory Days | 120 | 201 | 133 | 137 | 151 | 209 |
| Days Payable | 90 | 101 | 72 | 58 | 35 | 70 |
| Cash Conversion Cycle | 110 | 204 | 183 | 199 | 206 | 262 |
| Working Capital Days | 55 | 105 | 103 | 120 | 92 | 157 |
| ROCE % | 58% | 53% | 35% | 30% | 40% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Newspaper publication of financial result for quarter and half year ended September 2025
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
4 Nov - Audio recording of Q2/H1 FY2026 earnings call (Sept 30, 2025) posted Nov 4, 2025.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
4 Nov - Investor Presentation on Financial Results for the quarter and half year ended September 30, 2025
-
Unaudited Financial Result For The Quarter And Half Year Ended September 30, 2025
4 Nov - Approved unaudited results for quarter/H1 ended 30‑Sep‑2025: H1 revenue Rs5,202.39m; PBT Rs1,915.87m; limited review.
-
Board Meeting Outcome for Unaudited Standalone Financial Result For The Quarter And Half Year Ended Sep 2025
4 Nov - Board approved unaudited Q2/H1 results ended 30 Sep 2025; revenue ₹1,654.81m (Q2), ₹5,202.39m (H1).
Concalls
-
Nov 2025TranscriptNotesPPT REC
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
Product Portfolio
A) Contrast Media Intermediates (67.7% of FY24 revenue)[1]
Contrast media are chemical agents that enhance imaging clarity for diagnostic purposes, making tissues more visible under X-rays, CT scans, MRIs, and ultrasounds. The company supplies critical starting and advanced intermediates to the world's top contrast media manufacturers.